GSK opens new manufacturing plants in Singapore

pharmafile | July 5, 2019 | News story | Manufacturing and Production Asia, HIV, Singapore, anaemia, facilities, manufacturing, pharma 

British multinational GlaxoSmithKline has opened two new manufacturing plants in Singapore.

The UK firm has also expanded facilities at its Jurong site, as part of an effort to “accelerate the supply of new breakthrough medicines to patients globally.”

The $96 million investment will see GSK employ a process called ‘continuous manufacturing’ with the aim of reducing production time and thus enabling faster supply of medicines across the globe.

The new facilities will be focused on manufacturing active pharmaceutical ingredients (APIs) for HIV drugs and the anaemia therapy Daprodustat.

“Advanced manufacturing systems are pivotal for GSK to stay at the forefront of the pharmaceutical manufacturing sector,” said Mr Lim Hock Heng, vice-president and site director at GSK’s Pharmaceuticals Supply Chain Singapore.

“Further investment in digital manufacturing operations and processes will allow GSK to ensure efficient and high-quality production of our medicines.”

Louis Goss

Related Content

Touchlight completes expansion of one of world’s largest DNA manufacturing facilities in London

Touchlight, a company that focuses on pioneering enzymatic DNA production, has announced that it has …

FDA relaxes blood donation regulations for MSM

The US Food and Drug Administration (FDA) has released updated guidance for blood donation which …


Astellas receives positive CHMP opinion for symptomatic anaemia drug

Astellas and FibroGen have announced that the Committee for Medicinal Products for Human Use (CHMP) …

Latest content